Breaking News Instant updates and real-time market news.

ADMS

Adamas Pharmaceuticals

$25.86

0.86 (3.44%)

05:59
04/19/18
04/19
05:59
04/19/18
05:59

Adamas Pharmaceuticals announces final results from GOCOVRI Phase 3 study

Adamas Pharmaceuticals announced positive data from EASE LID 2, the company's two-year Phase 3 open-label study of GOCOVRI extended release capsules, the first and only medicine approved by the FDA for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Overall, results demonstrated that GOCOVRI was generally well tolerated and the treatment effect on motor complications, as measured by the Movement Disorder Society-Unified Parkinson's Disease Rating Scale, or MDS-UPDRS, Part IV, was maintained for up to two years. This effect was seen in all subgroups, including those switched to GOCOVRI from placebo or amantadine immediate release, or IR, as well as a subgroup of patients with uncontrollable dyskinesia after deep brain stimulation, or DBS, treatment. These data are planned to be presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders, or MDS, in Hong Kong, China. "The completed Phase 3 open-label study further expands our understanding of the benefit/risk profile of GOCOVRI," said Rajiv Patni, M.D., Chief Medical Officer of Adamas Pharmaceuticals, Inc. "The large reduction in dyskinesia and OFF, as assessed by the Part IV score of the MDS-UPDRS, was observed by the first visit at Week 8 and was sustained for two years. This durability is noteworthy given the known progression of motor complications. Nine percent of patients discontinued GOCOVRI due to an adverse drug reaction over this prolonged treatment period and the safety as well as tolerability remained consistent with that obtained from the 64-week data cut from December 2016. Lastly, by two years, 30 percent of patients increased their levodopa dose by an average of approximately 300 mg, suggesting that GOCOVRI treatment may allow neurologists to further optimize their patient's levodopa dose despite the occurrence of dyskinesia."

  • 19

    Apr

  • 25

    Apr

  • 25

    Apr

  • 12

    Jun

ADMS Adamas Pharmaceuticals
$25.86

0.86 (3.44%)

02/21/18
NORL
02/21/18
NO CHANGE
NORL
Outperform
Adamas Pharmaceuticals weakness a buying opportunity, says Northland
Northland analyst Carl Byrnes said he views Adamas Pharmaceuticals' weakness as a buying opportunity, stating that Gocovri is the only efficacious treatment for levodopa-induced dyskinesia and that Osmotica's Osmolex is not approved for the LID indication. Byrnes maintains his Outperform rating on Adamas shares.
03/15/18
MZHO
03/15/18
NO CHANGE
Target $49
MZHO
Buy
Adamas weakness on generic filer a buying opportunity, says Mizuho
Mizuho analyst Irina Koffler recommends using the weakness in shares of Adamas Pharmaceuticals after an undisclosed generic filer submitted an amended new drug application to sell a generic version of Gocovri as a buying opportunity. The drug is protected from generic competition until August 2024, at the earliest, Koffler tells investors in a research note. She keeps a Buy rating on Adamas with a $49 price target.
03/27/18
BOFA
03/27/18
INITIATION
Target $39
BOFA
Buy
Adamas Pharmaceuticals initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad started Adamas Pharmaceuticals with a Buy rating and $39 price target. The analyst's survey of 25 neurologists indicates favorable near-term sales growth for Gocovri. He also sees upside potential from the multiple sclerosis and epilepsy indications in the company's pipeline.
04/04/18
LEER
04/04/18
INITIATION
Target $31
LEER
Outperform
Adamas Pharmaceuticals initiated with an Outperform at Leerink
Leerink analyst Geoffrey Porges started Adamas Pharmaceuticals with an Outperform rating and $31 price target as he believes the recent pullback in the stock from the low-mid $30s offers an attractive opportunity for longer term investors that believe that Gocovri will ultimately succeed in capturing market share of the large PD dyskinesia market.

TODAY'S FREE FLY STORIES

TJX

TJX

$105.94

4.26 (4.19%)

11:19
08/21/18
08/21
11:19
08/21/18
11:19
Earnings
TJX raises FY19 revenue view to $38.2B-$38.4B from $37.7B-$37.9B, consensus $38B »

Still expects pretax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

TOL

Toll Brothers

$38.82

4.1 (11.81%)

11:18
08/21/18
08/21
11:18
08/21/18
11:18
Hot Stocks
Breaking Hot Stocks news story on Toll Brothers »

Toll Brothers sees FY18…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

STLR

Stellar Acquisition III

$10.50

(0.00%)

11:17
08/21/18
08/21
11:17
08/21/18
11:17
Conference/Events
Stellar Acquisition III to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
08/21/18
08/21
11:17
08/21/18
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOL

Toll Brothers

$39.13

4.41 (12.70%)

11:16
08/21/18
08/21
11:16
08/21/18
11:16
Hot Stocks
Breaking Hot Stocks news story on Toll Brothers »

Toll Brothers sees FY18…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
08/21/18
08/21
11:16
08/21/18
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
08/21/18
08/21
11:15
08/21/18
11:15
General news
Breaking General news story  »

Week of 8/21 4-Week Bill…

DISCA

Discovery

$28.83

0.91 (3.26%)

, AAPL

Apple

$214.78

-0.7 (-0.32%)

11:13
08/21/18
08/21
11:13
08/21/18
11:13
Recommendations
Fly Intel: Today's top analyst calls on Wall Street »

Check out today's…

DISCA

Discovery

$28.83

0.91 (3.26%)

AAPL

Apple

$214.78

-0.7 (-0.32%)

MSG

Madison Square Garden

$301.39

4.17 (1.40%)

MSGN

MSG Networks

$25.15

0.3 (1.21%)

TSLA

Tesla

$319.25

10.75 (3.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

TOL

Toll Brothers

$39.20

4.48 (12.90%)

11:13
08/21/18
08/21
11:13
08/21/18
11:13
Hot Stocks
Toll Brothers says current backlog gives good visibility through 1H19 »

The company projects FY…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

NFLX

Netflix

$339.01

11.26 (3.44%)

, AAPL

Apple

$214.71

-0.77 (-0.36%)

11:10
08/21/18
08/21
11:10
08/21/18
11:10
Hot Stocks
Analyst sees favorable setup ahead for Netflix on international subscriptions »

In a research note this…

NFLX

Netflix

$339.01

11.26 (3.44%)

AAPL

Apple

$214.71

-0.77 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

ROST

Ross Stores

$92.32

-0.01 (-0.01%)

11:10
08/21/18
08/21
11:10
08/21/18
11:10
Options
Defensive option play opened in Ross Stores ahead of earnings »

Defensive option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

11:10
08/21/18
08/21
11:10
08/21/18
11:10
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

TJX

TJX

$105.50

3.82 (3.76%)

11:09
08/21/18
08/21
11:09
08/21/18
11:09
Hot Stocks
Breaking Hot Stocks news story on TJX »

TJX still sees buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

DISCA

Discovery

$28.80

0.88 (3.15%)

, AAPL

Apple

$214.70

-0.78 (-0.36%)

11:09
08/21/18
08/21
11:09
08/21/18
11:09
Recommendations
Fly Intel: Today's top analyst calls on Wall Street »

Check out today's…

DISCA

Discovery

$28.80

0.88 (3.15%)

AAPL

Apple

$214.70

-0.78 (-0.36%)

MSG

Madison Square Garden

$301.58

4.36 (1.47%)

MSGN

MSG Networks

$25.15

0.3 (1.21%)

TSLA

Tesla

$318.95

10.45 (3.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

TJX

TJX

$105.65

3.97 (3.90%)

11:05
08/21/18
08/21
11:05
08/21/18
11:05
Hot Stocks
TJX CEO Ernie Herrman says Q3 'off to a very strong start' »

Comment taken from the Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

PAYX

Paychex

$72.53

0.21 (0.29%)

11:00
08/21/18
08/21
11:00
08/21/18
11:00
Options
Paychex calls active »

Paychex calls active.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

NVDA

Nvidia

$251.67

3.82 (1.54%)

, BIDU

Baidu

$225.00

1.37 (0.61%)

10:57
08/21/18
08/21
10:57
08/21/18
10:57
Hot Stocks
Citron remains cautious on Nvidia, repeats $200 per share forecast »

In a newly published…

NVDA

Nvidia

$251.67

3.82 (1.54%)

BIDU

Baidu

$225.00

1.37 (0.61%)

BABA

Alibaba

$178.80

2.59 (1.47%)

TCEHY

Tencent

$0.00

(0.00%)

FB

Facebook

$173.87

1.37 (0.79%)

GOOG

Alphabet

$1,215.21

7.67 (0.64%)

GOOGL

Alphabet Class A

$1,230.17

8.99 (0.74%)

MSFT

Microsoft

$106.99

0.12 (0.11%)

AMZN

Amazon.com

$1,891.43

15.98 (0.85%)

NFLX

Netflix

$338.51

10.76 (3.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 23

    Aug

  • 04

    Sep

  • 05

    Sep

  • 06

    Sep

  • 10

    Sep

  • 12

    Sep

  • 13

    Sep

  • 18

    Sep

  • 20

    Sep

  • 28

    Oct

DWDP

DowDuPont

$69.29

0.81 (1.18%)

10:50
08/21/18
08/21
10:50
08/21/18
10:50
Options
DowDuPont draws call buyers as shares see strength »

DowDuPont draws call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

XXII

22nd Century

$2.36

0.08 (3.51%)

10:42
08/21/18
08/21
10:42
08/21/18
10:42
Hot Stocks
22nd Century reports order for 3.6M SPECTRUM research cigarette »

22nd Century Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$173.61

1.11 (0.64%)

10:41
08/21/18
08/21
10:41
08/21/18
10:41
Periodicals
Facebook is rating the trustworthiness of its users, Washington Post reports »

Facebook has started to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 06

    Sep

  • 18

    Sep

AMTD

TD Ameritrade

$56.56

-3.6 (-5.98%)

10:40
08/21/18
08/21
10:40
08/21/18
10:40
Options
Heavy trading in TD Ameritrade as the stock comes under fire »

Heavy trading in TD…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNIT

Uniti Group

$21.09

0.57 (2.78%)

10:30
08/21/18
08/21
10:30
08/21/18
10:30
Options
Notable put buying in Uniti Group »

Notable put buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZZA

Papa John's

$42.71

-0.01 (-0.02%)

10:29
08/21/18
08/21
10:29
08/21/18
10:29
Rumors
Rumor moving shares of Papa John's »

Rumor: Papa John's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAL

American Airlines

$40.16

0.16 (0.40%)

10:27
08/21/18
08/21
10:27
08/21/18
10:27
Hot Stocks
American Airlines announces expanded European footprint, modified Asia service »

American Airlines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

DXCM

DexCom

$133.50

1.29 (0.98%)

10:25
08/21/18
08/21
10:25
08/21/18
10:25
Conference/Events
DexCom management to participate in a conference call with Leerink »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 27

    Aug

  • 12

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.